Endocrine Research Updates

For Medical Professionals

Words related to clinical trials
Doug Lowy, MD, and Keith T. Flaherty, MD, Comment
The National Cancer Institute (NCI)-supported precision medicine trial known as NCI-MATCH (Molecular Analysis for Therapy Choice) will begin enrollment in July 2015. The goal of the trial is to determine whether select cancer treatments are effective against specific molecular abnormalities, regardless of tumor type. Learn more about the trial and how patients can enroll.
Environmental chemicals are messing with our health.
Avoidance of Endocrine Disrupting Chemicals (EDCs) requires greater due diligence and wiser choices especially with regard to children and pregnant women.
Ongoing exposure to endocrine disrupting chemicals like BPA lead to a number of diseases including diabetes, early onset of puberty, cancer, neurobehavioral disorders, and thyroid disorders.
New Drug Application for MM-398 in Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals, Inc., has submitted a New Drug Application (NDA) for MM-398 (irinotecan liposome injection) in the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. Merrimack has requested a priority review of the NDA.
Bariatric Surgery Before Pregnancy
Bariatric surgery was linked to positive outcomes in pregnancy, such a reduced risk for gestational diabetes and excessive fetal growth, according to data from a population-based study. However, this study was also associated with negative outcomes, including an increased risk for small-for-gestational age infants and possibly increased mortality. These findings suggest the need for increased monitoring during pregnancy.
Earlier Menopause Linked to Exposure to Endocrine Disrupting Chemicals
Women with high levels of endocrine-disrupting chemicals experienced menopause 2 to 4 years earlier than women with lower levels of these chemicals, according to a cross-sectional study using data from using the National Health and Nutrition Examination Survey (NHANES). The findings were published in PLoS ONE.
The t:flex™ Insulin Pump
The t:flex™ Insulin Pump was approved for marketing by the U.S. Food and Drug Administration, making it the largest-capacity insulin pump available in the United States.
Overweight young boy that is upset
Approximately one-quarter to one-third of all children who have obesity and enter weight management programs are depressed, according to 2 studies.
two business professionals signing a document
DreaMed Diabetes has signed a licensing agreement with Medtronic that will allow its closed-loop artificial pancreas technology, called GlucoSitter™, to be used in Medtronic’s insulin pumps.
sad looking teenage girl
Management of type 1 diabetes is particularly challenging during adolescence, a time when teens are dealing with physical changes among other issues.
Estrogen, transgender hormone therapy is safe
One of the most often cited reasons by medical providers for hesitation in providing hormone therapy to transgender individuals is the fear of harm. The review demonstrates that hormone therapy is relatively safe, at least as far as the modest literature out there can determine.
Insulin injection pen
An estimated 100,000 insulin-related hypoglycemia and errors occur annually
Insulin-related hypoglycemia and errors (IHEs) are significant causes of emergency department (ED) visits and hospitalizations in insulin-treated people with diabetes.
Overweight young girl watching television
VBLOC vagal blocking therapy delivered via the Maestro System is now approved to treat adults age 18 to 65 years with a body mass index (BMI) of 40 to 45 kg/m2 or >35 kg/m2 and 1 or more obesity-related complications.
Medicine vials and syringe
American Society of Bariatric Physicians Applauds Approval
Saxenda (liraglutide [rDNA origin] injection) is now approved for chronic weight management in addition to a reduced-calorie diet and physical activity in adults with a body mass index (BMI) of .....
Scientist or tech holds liquid biological sample in gloved hands
A clinical trial is examining whether an artificial pancreas improves nighttime blood glucose levels in patients with type 1 diabetes.
Pharmacist and customer looking at medication box
Younger adults with diabetes (age 18 to 39 years) are less likely than older patients to take medication to control their glucose levels or to see a doctor biannually.
An investigational oral formulation of octreotide was found to be safe and effective in the treatment of acromegaly in a phase 3 open-label study published online ahead of print in the Journal of Clinical Endocrinology & Metabolism.
Young woman looking in the refrigerator at late evening
The U.S. Food and Drug Administration (FDA) expanded the approved uses of Vyvanse® (lisdexamfetamine dimesylate) to include treatment of moderate-to-severe binge-eating disorder in adults, making it the first medication approved to treat this condition.
Brain outline in red pencil
People who develop diabetes in middle-age are more likely to experience significant memory and cognitive problems over the next 20 years compared to people without diabetes in midlife, according to a prospective cohort study.
Pancreatic islet cell normal and type 1 diabetic
Researchers discussed the latest advances in cell replacement therapy for the treatment of type 1 diabetes in the January issue of Endocrinology.
Glucometer pictured as part of glucose management
The findings of this important paper emphasize one specific word: early. It is important to treat these patients with type 1 aggressively and early, when they are either adolescent or young adults, or as soon as they are diagnosed if they are diagnosed in their 20s.